Skip to main content
SpringerLink
Log in

Testosterone Deficiency or Male Hypogonadism

  • Chapter
  • First Online:
Endocrine Hypertension

Part of the book series: Contemporary Endocrinology ((COE))

  • 2491 Accesses

Abstract

Testosterone deficiency (TD) may represent a cardiovascular risk factor, as it has become a frequently diagnosed condition in the current obesity epidemic. Men diagnosed with TD often have comorbidities including hypertension, metabolic syndrome, and sleep apnea. Apart from sexual aspects including lack of sex drive and erectile dysfunction, challenging aspects in diagnosing and treating patients with TD include interindividual variation of symptoms combined with lack of symptom correlation with serum testosterone levels. Replacement therapy with testosterone has beneficial metabolic effects with an improved glycemic profile and improved cardiac function in selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383–90.

    Article  PubMed  CAS  Google Scholar 

  2. Barrett-Connor E, Stuenkel C. Hormones and heart disease in women: heart and estrogen/progestin replacement study in perspective. J Clin Endocrinol Metab. 1999;84:1848–53.

    Article  PubMed  CAS  Google Scholar 

  3. Yildiz O, Seyrek M. Vasodilating mechanisms of testosterone. Exp Clin Endocrinol Diabetes. 2007;115:1–6.

    Article  PubMed  CAS  Google Scholar 

  4. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and ­metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–83.

    Article  PubMed  CAS  Google Scholar 

  5. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(3):153–64.

    Article  PubMed  CAS  Google Scholar 

  6. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673–81.

    Article  PubMed  CAS  Google Scholar 

  7. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–75.

    Article  PubMed  CAS  Google Scholar 

  8. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578–87.

    Article  PubMed  CAS  Google Scholar 

  9. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341–53.

    Article  PubMed  CAS  Google Scholar 

  10. Friedrich N, Rosskopf D, Brabant G, Völzke H, Nauck M, Wallaschofski H. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes. 2010;118:266–73.

    Article  PubMed  CAS  Google Scholar 

  11. Canale D, Caglieresi C, Moschini C, Liberati CD, Macchia E, Pinchera A, et al. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin Endocrinol (Oxf). 2005;63:356–61.

    Article  CAS  Google Scholar 

  12. Zitzmann M. Pharmacogenetics of testosterone replacement therapy. Pharmacogenomics. 2009;10:1341–9.

    Article  PubMed  CAS  Google Scholar 

  13. Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res. 2009;37:52–61.

    Article  PubMed  CAS  Google Scholar 

  14. Liu PP, Fukuoka M. Sex hormones as novel risk biomarkers for atherosclerosis in peripheral vascular disease. J Am Coll Cardiol. 2007;50:1077–9.

    Article  PubMed  CAS  Google Scholar 

  15. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:80–8.

    Article  PubMed  CAS  Google Scholar 

  16. Bours SP, van Geel PA, Geusens PP, et al. Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab. 2011;96(5):1360–7.

    Article  PubMed  CAS  Google Scholar 

  17. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, Wilson PW, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006;119(5):426–33.

    Article  PubMed  CAS  Google Scholar 

  18. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995;95:2886–95.

    Article  PubMed  CAS  Google Scholar 

  19. Romagnoli E, Del Fiacco R, Russo S, Piemonte S, Fidanza F, Colapietro F, et al. Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J Rheumatol. 2011;38(8):1671–9.

    Article  PubMed  Google Scholar 

  20. Stellato R-K, Feldman H-A, Hamdy O, Horton E-S, McKinlay J-B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23:490–4.

    Article  PubMed  CAS  Google Scholar 

  21. O’Connell MD, Ravindrarajah R, Tajar A, Wu FC. Low testosterone in ageing men: a modifiable risk factor for frailty? Trends Endocrinol Metab. 2011;22(12):491–8.

    Article  PubMed  CAS  Google Scholar 

  22. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–76.

    Article  PubMed  CAS  Google Scholar 

  23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.

    Article  PubMed  CAS  Google Scholar 

  24. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86(9):4078–88.

    Article  PubMed  CAS  Google Scholar 

  25. Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc. 2000;75 Suppl:S83–7.

    Google Scholar 

  26. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46:80–7.

    Article  PubMed  Google Scholar 

  27. Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med. 2007;120:835–40.

    Article  PubMed  CAS  Google Scholar 

  28. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–9.

    Article  PubMed  CAS  Google Scholar 

  29. Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol. 2012;187(4):1369–73.

    Article  PubMed  CAS  Google Scholar 

  30. Mauras N, Hayes V, Welch S, Veldhuis J, Urban R. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998;83:1886–92.

    Article  PubMed  CAS  Google Scholar 

  31. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81:3469–75.

    Article  PubMed  CAS  Google Scholar 

  32. Bhasin S, Storer TW, Berman N, Yarasheski KE, Cleveneger B, Casaburi RA. A replacement dose of testosterone increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407–13.

    Article  PubMed  CAS  Google Scholar 

  33. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose–response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–81.

    PubMed  CAS  Google Scholar 

  34. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154–64.

    PubMed  CAS  Google Scholar 

  35. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab. 1997;82:682–5.

    Article  PubMed  CAS  Google Scholar 

  36. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999;22(5 Suppl):110–6.

    PubMed  CAS  Google Scholar 

  37. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992;2:675–82.

    Article  PubMed  CAS  Google Scholar 

  38. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab. 1998;12:441–51.

    Article  PubMed  CAS  Google Scholar 

  39. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab. 1996;81(5):1821–6.

    Article  PubMed  CAS  Google Scholar 

  40. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358–65.

    Article  PubMed  CAS  Google Scholar 

  41. Marin P. Testosterone and regional fat distribution. Obes Res. 1995;3 Suppl 4:609–12.

    Google Scholar 

  42. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16:991–7.

    PubMed  CAS  Google Scholar 

  43. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992;1:329–36.

    PubMed  CAS  Google Scholar 

  44. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol. 1999;50:629–35.

    Article  CAS  Google Scholar 

  45. Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.

    Article  PubMed  CAS  Google Scholar 

  46. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men Testosterone Gel Study Group. J Clin Endocrinol Metab. 2000;85(8):2839–53.

    Article  PubMed  CAS  Google Scholar 

  47. Rolf C, von Eckardstein S, Koken U, Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol. 2002;146:505–11.

    Article  PubMed  CAS  Google Scholar 

  48. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7.

    Article  PubMed  CAS  Google Scholar 

  49. McLachlan RI, O’Donnell L, Meachem SJ, Stanton PG, de Kretser DM, Pratis K, et al. Identification of specific sites of hormonal regulation in spermatogenesis in rats, monkeys, and man. Recent Prog Horm Res. 2002;57:149–79.

    Article  PubMed  CAS  Google Scholar 

  50. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab. 2004;89(2):718–26.

    Article  PubMed  CAS  Google Scholar 

  51. Garaulet M, Perex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143(5):657–66.

    Article  PubMed  CAS  Google Scholar 

  52. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5:551–9.

    Article  PubMed  CAS  Google Scholar 

  53. Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest. 2002;25:855–61.

    PubMed  CAS  Google Scholar 

  54. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006;1083:77–110.

    Article  PubMed  CAS  Google Scholar 

  55. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8.

    Article  PubMed  CAS  Google Scholar 

  56. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.

    Article  PubMed  CAS  Google Scholar 

  57. Yamada T, Katagiri H, Ishigaki Y, Ogihara T, Imai J, Uno K, et al. Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: neuronal involvement in food-intake regulation. Cell Metab. 2006;3:223–9.

    Article  PubMed  CAS  Google Scholar 

  58. Lanfranco F, Motta G, Minetto MA, et al. Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol. 2010;2010:474518.

    PubMed  Google Scholar 

  59. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673–80.

    Article  PubMed  CAS  Google Scholar 

  60. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147:141–54.

    Article  PubMed  CAS  Google Scholar 

  61. Xu XF, De Pergola G, Björntorp P. Testosterone increases lipolysis and the number of beta-adrenoreceptors in male rat adipocytes. Endocrinology. 1991;128:379–82.

    Article  PubMed  CAS  Google Scholar 

  62. Chen X, Li X, Huang HY, Li X, Lin JF. Effects of testosterone on insulin receptor substrate-1 and glucose transporter 4 expression in cells sensitive to insulin. Zhonghua Yi Xue Za Zhi. 2006;86:1474–7.

    PubMed  CAS  Google Scholar 

  63. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.

    Article  PubMed  CAS  Google Scholar 

  64. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28:1636–42.

    Article  PubMed  CAS  Google Scholar 

  65. Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia. 2003;46:31–9.

    PubMed  CAS  Google Scholar 

  66. Behre HM, Simoni M, Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clin Endocrinol (Oxf). 1997;47:237–40.

    Article  CAS  Google Scholar 

  67. Jockenhövel F, Blum WF, Vogel E, et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab. 1997;82:2510–3.

    Article  PubMed  Google Scholar 

  68. Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev. 2004;5:197–216.

    Article  PubMed  CAS  Google Scholar 

  69. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes. 2001;25:1782–8.

    Article  CAS  Google Scholar 

  70. Eisenmann JC. Secular trends in variables associated with the metabolic syndrome of North American children and adolescents: a review and synthesis. Am J Hum Biol. 2003;15:786–94.

    Article  PubMed  Google Scholar 

  71. Carr DB, Utzschneider KM, Hull RL. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087–94.

    Article  PubMed  CAS  Google Scholar 

  72. Cassells HB, Haffner SM. The metabolic syndrome: risk factors and management. J Cardiovasc Nurs. 2006;21:306–13.

    PubMed  Google Scholar 

  73. Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.

    Article  PubMed  CAS  Google Scholar 

  74. Stern M, Williams K, Gonzalez-Villalpando C. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676–81.

    Article  PubMed  Google Scholar 

  75. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.

    Article  PubMed  CAS  Google Scholar 

  76. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85:3276–82.

    Article  PubMed  Google Scholar 

  77. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.

    Article  PubMed  CAS  Google Scholar 

  78. Corona G, Monami M, Rastrelli G, Aversa A, Storza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2010;34:528–40.

    Article  PubMed  CAS  Google Scholar 

  79. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–19.

    Article  PubMed  CAS  Google Scholar 

  80. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012;97(1):179–89.

    Article  PubMed  CAS  Google Scholar 

  81. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58(16):1674–81.

    Article  PubMed  CAS  Google Scholar 

  82. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.

    Article  PubMed  CAS  Google Scholar 

  83. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.

    Article  PubMed  CAS  Google Scholar 

  84. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex, sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled randomized study. J Am Coll Cardiol. 2009;54(10):919–27.

    Article  PubMed  CAS  Google Scholar 

  85. Kaltsas G, Vgontzas A, Chrousos G. Fatigue, endocrinopathies, and metabolic disorders. PM R. 2010;2(5):393–8.

    Article  PubMed  Google Scholar 

  86. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnoea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005;9(3):211–24.

    Article  PubMed  Google Scholar 

  87. Vgontzas AN, Pejovic S, Zoumakis E, Lin HM, Bentley CM, Bixler EO, et al. Hypothalamic-pituitary adrenal axis activity in obese men with and without sleep apnea: effects of continuous positive airway pressure therapy. J Clin Endocrinol Metab. 2007;92:4199–207.

    Article  PubMed  CAS  Google Scholar 

  88. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest. 2008;38(8):585–95.

    Article  PubMed  CAS  Google Scholar 

  89. Trakada G, Chrousos G, Pejovic S, Vgontzas A. Sleep apnea and its association with the stress system, inflammation, insulin resistance, and visceral obesity. Sleep Med Clin. 2007;2(2):251–61.

    Article  PubMed  Google Scholar 

  90. Yanase T, Fan W, Kyoya K, Min L, Takayanagi R, Kato S, et al. Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol. 2008;109:254–7.

    Article  PubMed  CAS  Google Scholar 

  91. Bourghardt J, Wilhelmson AS, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–37.

    Article  PubMed  CAS  Google Scholar 

  92. Dati E, Baroncelli GI, Mora S, Russo G, Baldinotti F, Parrini D, et al. Body composition and metabolic profile in women with complete androgen insensitivity syndrome. Sex Dev. 2009;3:188–93.

    Article  PubMed  CAS  Google Scholar 

  93. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, et al. The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29:1591–8.

    Article  PubMed  Google Scholar 

  94. Ishikawa T, Yamaguchi K, Kondo Y, Takenaka A, Fujisawa M. Metabolic syndrome in men with Klinefelter’s syndrome. Urology. 2008;71:1109–13.

    Article  PubMed  Google Scholar 

  95. Bojesen A, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. J Clin Endocrinol Metab. 2004;89:3830–4.

    Article  PubMed  CAS  Google Scholar 

  96. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232–6.

    Article  PubMed  CAS  Google Scholar 

  97. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75.

    Article  PubMed  CAS  Google Scholar 

  98. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25:55–60.

    Article  PubMed  CAS  Google Scholar 

  99. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84(2):573–7.

    Article  PubMed  CAS  Google Scholar 

  100. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12:5–12.

    Article  PubMed  Google Scholar 

  101. Zitzmann M, Nieschlag E. Testosterone substitution: current modalities and perspectives. J Reprod Med Endocrinol. 2006;3:109–16.

    CAS  Google Scholar 

  102. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427–48.

    PubMed  CAS  Google Scholar 

  103. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–85.

    Article  PubMed  CAS  Google Scholar 

  104. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602–12.

    Article  CAS  Google Scholar 

  105. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab. 1993;77:776–9.

    Article  PubMed  CAS  Google Scholar 

  106. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease. A scientific statement from the American Heart Association. Circulation. 2012;125(8):1058–72.

    Article  PubMed  Google Scholar 

  107. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003;58:632–8.

    Article  CAS  Google Scholar 

  108. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab. 2008;23(6):769–80.

    Article  CAS  Google Scholar 

  109. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.

    PubMed  CAS  Google Scholar 

  110. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007;34:549–53, vi.

    Google Scholar 

  111. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–41.

    Article  PubMed  CAS  Google Scholar 

  112. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469–78.

    Article  PubMed  CAS  Google Scholar 

  113. McGriff NJ, Csako G, Kabbani M, Diep L, Chrousos GP, Pucino F. Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: a review of the literature. Pharmacotherapy. 2001;21(11):1425–35.

    Article  PubMed  CAS  Google Scholar 

  114. Carruthers M. Time for international action on treating testosterone deficiency syndrome. Aging Male. 2009;12:21–8.

    Article  PubMed  CAS  Google Scholar 

  115. Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med. 2008;5:998–1012.

    Article  PubMed  CAS  Google Scholar 

  116. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007;92:2519–25.

    Article  PubMed  CAS  Google Scholar 

  117. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887–9.

    Article  PubMed  CAS  Google Scholar 

  118. Wang C, Christenson P, Swerdloff R. Editorial: clinical relevance of racial and ethnic differences in sex steroids. J Clin Endocrinol Metab. 2007;92:2433–5.

    Article  PubMed  CAS  Google Scholar 

  119. Tsai HK, D’Amico AV, Sadetsky N, Chen M-H, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–24.

    Article  PubMed  Google Scholar 

  120. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. ­Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: a Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60:194–201.

    Article  PubMed  Google Scholar 

  121. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742–5.

    Article  PubMed  Google Scholar 

  122. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.

    Article  PubMed  CAS  Google Scholar 

  123. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–8.

    Article  PubMed  CAS  Google Scholar 

  124. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf). 2011;74(3):377–83.

    Article  CAS  Google Scholar 

  125. Axelsson J, Ingre M, Akerstedt T, Holmback U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab. 2005;90:4530–5.

    Article  PubMed  CAS  Google Scholar 

  126. Penev PD. Association between sleep and morning testosterone levels in older men. Sleep. 2007;30:427–32.

    PubMed  Google Scholar 

  127. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J Clin Endocrinol Metab. 1989;68:352–8.

    Article  PubMed  CAS  Google Scholar 

  128. Gianotti L, Pivetti S, Lanfranco F, Tassone F, Navone F, Vittori E, et al. Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab. 2002;87:5052–7.

    Article  PubMed  CAS  Google Scholar 

  129. Sievers C, Klotsche J, Pieper L, Schneider HJ, März W, Wittchen HU, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol. 2010;163:699–708.

    Article  PubMed  CAS  Google Scholar 

  130. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007;50:2076–84.

    Article  PubMed  CAS  Google Scholar 

  131. Torrens JI, Sutton-Tyrrell K, Zhao X, Matthews K, Brockwell S, Sowers M, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women’s Health Across the Nation. Menopause. 2009;16:257–64.

    Article  PubMed  Google Scholar 

  132. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207:318–27.

    Article  PubMed  CAS  Google Scholar 

  133. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones ? Endocr Rev. 2012;33(3):314–77.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, University of Mississippi Medical Center, Jackson, MS, USA

    Christian A. Koch

  2. Center for Reproductive Medicine and Andrology, Westfaelische Wilhelms University, Domagkstrasse 11, Muenster, 48149, Germany

    Michael Zitzmann

Authors
  1. Christian A. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Zitzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Zitzmann .

Editor information

Editors and Affiliations

  1. Dept. Medicine, Div. Endocrinology, Diabetes &, University of Mississippi Medical Center, N. State Street 2500, Jackson, 39216, Mississippi, USA

    Christian A Koch

  2. UNESCO Chair on Adolescent Health Care, Division of Endocrinology, University of Athens Medical School, Aghia Sophia Children's Hospital, Athens, 11527, Greece

    George P Chrousos

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Koch, C.A., Zitzmann, M. (2013). Testosterone Deficiency or Male Hypogonadism. In: Koch, C., Chrousos, G. (eds) Endocrine Hypertension. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-548-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-548-4_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-547-7

  • Online ISBN: 978-1-60761-548-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation